← Back to Search

Growth Hormone Releasing Hormone Analog

Immediate group for Mild Cognitive Impairment

Phase 2

Waitlist Available

Led By Fred Sattler, MD

Research Sponsored by University of California, San Diego

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months and 12 months

Awards & highlights

Study Summary

This trial will test if a combination of tesamorelin and a text-messaging application can improve memory and thinking in HIV patients.

Eligible Conditions

Mild Cognitive Impairment

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months and 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months and 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Neurocognitive performance

Secondary outcome measures

Biomarkers of visceral adipose tissue (VAT)-related inflammation and immune activation, metabolic parameters, and neuronal integrity

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Immediate groupActive Control1 Intervention

1.4mg of tesamorelin is injected once a day for 6 months, then no treatment is given for 6 months

Group II: Deferred groupPlacebo Group1 Intervention

No treatment is given for 6 months, then 1.4mg of tesamorelin is injected once a day for 6 months

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of California, San DiegoLead Sponsor

1,124 Previous Clinical Trials

1,552,818 Total Patients Enrolled

University of Southern CaliforniaOTHER

906 Previous Clinical Trials

1,596,084 Total Patients Enrolled

University of California, San FranciscoOTHER

2,507 Previous Clinical Trials

15,238,467 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many study participants have enrolled in the trial thus far?

"Affirmative. Clinicaltrials.gov reveals that this trial, first promulgated on February 15th 2017 and most recently modified on July 6th 2022, is actively recruiting 100 participants across 4 sites."

Answered by AI

Is the Immediate group a reliable option for those seeking treatment?

"Immediate group's safety has been assessed with a rating of 2, indicating there is some data available on this intervention's security but no evidence testifying to its efficacy."

Answered by AI

What other investigations have been conducted to explore the effects of Immediate group?

"At present, Immediate group is being researched in 4 active clinical trials. None of the studies are currently in Phase 3. Most of these studies take place within New york City limits, however there are also 8 other sites around the country which have dedicated research projects concerning this medication."

Answered by AI

Does the research team currently need additional participants for their project?

"As publicly documented on clinicaltrials.gov, this trial is currently open to enrollment and has been since February 15th 2017. The information was most recently updated on July 6th 2022."

Answered by AI

How many healthcare facilities are trialing this experiment?

"This medical trial is being conducted in four distinct locations, including the HIV Neurobehavioral Research Program (HNRP) based in San Diego, Keck School of Medicine of the University of Southern California located in Los Angeles and University of California, San Francisco situated in San Francisco. Additionally there are other research sites participating."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

Ronald Ellis 2017. "Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02572323.